证券之星消息，截至2025年12月16日收盘，国际医学(000516)报收于4.5元，下跌1.1%，换手率0.52%， 成交量11.38万手，成交额5125.48万元。 12月16日的资金流向数据方面，主力资金净流出408.2万元，占总成交额7.96%，游资资金净流出185.04 万元，占总成交额3.61%，散户资金净流入593.23万元，占总成交额11.57%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。国际医学（000516）主营业务：大健康医疗服务和现代医学技术转化应用。 该股最近90天内共有2家机构给出评级，增持评级2家；过去 ...

国际医学融资融券信息显示，融资方面，当日融资买入1373.6万元，融资偿还1695.19万元，融资净偿还 321.6万元。融券方面，融券卖出0.0股，融券偿还100.0股，融券余量1.0万股，融券余额4.7万元。融资 融券余额3.11亿元。 近5日融资融券数据一览见下表： 证券之星消息，截至2025年12月4日收盘，国际医学(000516)报收于4.7元，下跌3.29%，换手率1.02%， 成交量22.54万手，成交额1.07亿元。 12月4日的资金流向数据方面，主力资金净流出673.79万元，占总成交额6.29%，游资资金净流入452.13 万元，占总成交额4.22%，散户资金净流入221.66万元，占总成交额2.07%。 近5日资金流向一览见下表： 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资 ...

Core Viewpoint - International Medical (000516) has shown a mixed performance in recent trading sessions, with fluctuations in stock price and varying capital flows, indicating potential volatility in investor sentiment [1][2]. Financial Performance - As of the latest report, International Medical's total market value is 10.881 billion yuan, with a net asset value of 3.21 billion yuan [3]. - The company reported a net profit of -165 million yuan, reflecting a year-on-year increase of 4.98%, while its main revenue decreased by 15.95% to 2.034 billion yuan [3]. - The gross profit margin stands at 7.8%, significantly lower than the industry average of 35.92% [3]. Capital Flow Analysis - On October 21, 2025, the stock price closed at 4.86 yuan, with a slight increase of 0.62%. The main capital flow showed a net outflow of 2.2612 million yuan, accounting for 3.83% of the total transaction volume [1][2]. - Over the past five days, the stock has experienced varying capital flows, with notable net inflows from speculative funds on certain days, while main capital has seen consistent outflows [2]. Industry Comparison - In comparison to the healthcare services industry, International Medical ranks low in several key metrics, including net profit and return on equity (ROE), with a ROE of -4.6% compared to the industry average of 2.19% [3]. - The company's price-to-earnings ratio (P/E) is -32.98, indicating a lack of profitability relative to its peers [3]. Analyst Ratings - Recently, two institutions have provided ratings for the stock, with one buy rating and one hold rating, suggesting a cautious outlook among analysts [4].

Core Viewpoint - The company positions itself as a representative comprehensive medical service listed company in the secondary market, focusing on health services and modern medical technology application [1] Group 1: Company Positioning and Services - The company has established a health service platform covering the entire lifecycle, from medical services to rehabilitation and elderly care, with a service capacity of 10,000 beds [1] - The company has built a comprehensive medical service network centered in Xi'an, rooted in Shaanxi, and radiating to the central and western regions of China [1] Group 2: Financial Performance and Shareholder Returns - The company has distributed cash dividends 16 times since its listing, totaling 576 million yuan [1] - Due to the impact of newly launched medical projects, the company's revenue has not yet covered operational costs, resulting in net losses and no cash dividends being distributed [1] - The company has been actively repurchasing shares and implementing stock incentives for core teams, signaling confidence to the market [1] Group 3: Communication with Investors - The company emphasizes communication with investors through performance briefings, establishing an investor relations public account, and organizing activities for investors to visit the company [1]